1.Study on the medication rules of traditional Chinese medicine in treating breast cancer based on data mining
Yuan LI ; Lin QIAN ; Chao TIAN ; Tao WU ; Lyuhui HU ; Bingmei ZHU ; Zhihua YE ; Zhizhen TAO ; Min YANG ; Qinxi LIU ; Bihui YANG ; Hang LUO ; Fan QU ; Yi YANG
China Modern Doctor 2025;63(24):68-72,129
Objective To analyze the medication rules of traditional Chinese medicine in treating breast cancer based on real-world data mining.Methods Inpatients with breast cancer who received traditional Chinese medicine treatment at the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine from January 2017 to December 2021 were selected.Python 3.10 software was used to mine traditional Chinese medicine prescription data;SPSS 23.0 software was applied for descriptive analysis,and systematic cluster analysis was performed on high-frequency drugs.Results A total of 3026 consultation records of inpatients with breast cancer were collected.The main traditional Chinese medicine syndrome diagnosis of"predominantly liver depression and Qi stagnation"accounted for 60.94%of the total consultations.A total of 240 kinds of traditional Chinese medicine were used,with a cumulative frequency of 35 462 times.Among them,29 kinds of traditional Chinese medicine such as Danggui,Fuling,Baizhu,Chaihu had a cumulative usage frequency exceeding 300 times.Regarding the four natures of drugs,cold-natured(43.55%),warm-natured(30.05%),and neutral-natured(23.34%)drugs were predominant;In terms of five flavors,sweet(46.12%),bitter(30.91%),and pungent(20.02%)were the main ones.The most frequently used drugs were tonifying herbs(32.77%),followed by heat-clearing herbs(15.96%)and phlegm-resolving herbs(14.71%).Systematic cluster analysis yielded 7 groups of drug combinations.Conclusion In real-world clinical practice,traditional Chinese medicine for breast cancer mainly uses tonifying herbs,reflecting the traditional Chinese medicine principle of"strengthening healthy Qi and cultivating the root"in treating tumors.The four natures and five flavors of drugs follow syndrome differentiation and the combination of cold and heat.The clustered drug combinations have extensive therapeutic effects,covering various syndromes of breast cancer at different stages,which can provide a reference for clinical medication.
2.Mechanism of BIM-induced ibrutinib resistance in chronic lymphocytic leukemia
Jiale ZHANG ; Bihui PAN ; Jiazhu WU ; Yilin KONG ; Li WANG ; Wei XU
Chinese Journal of Hematology 2025;46(2):152-160
Objective:To investigate the relationship between the BCL2 family protein BIM and ibrutinib resistance in chronic lymphocytic leukemia (CLL) and to analyze its regulatory mechanisms on apoptosis and autophagy.Methods:RNA sequencing (RNA-seq) was used to examine changes in the expression of BCL2 family proteins in samples from patients with CLL, MEC1 cell lines, and ibrutinib-resistant cell lines (MR). Western blot was used to analyze changes in BIM protein expression during apoptosis in MR. shRNA knockdown was used to assess the effects of BIM on cell proliferation and apoptosis. RNA-seq and the autophagy inhibitor chloroquine treatment were used to study autophagy-related changes in MR.Results:BIM expression was significantly downregulated before and after drug resistance in CLL primary cells and MEC1 cell lines ( P<0.0001). Knockdown of BIM in CLL cells inhibited ibrutinib-induced apoptosis and promoted cell proliferation ( P<0.05 for both). In addition, protective autophagy was increased in MR and apoptosis was increased after administration of chloroquine and small interfering RNA. The increased expression of LC3-Ⅱ protein in BIM-knockdown cell lines ( P<0.01) suggested that reduction of BIM may mediate autophagy activation. Conclusion:Downregulation of BIM may be a key factor in promoting ibrutinib resistance in CLL by activating protective autophagy. These findings provided a potential target for improving CLL treatment.
3.Study on the medication rules of traditional Chinese medicine in treating breast cancer based on data mining
Yuan LI ; Lin QIAN ; Chao TIAN ; Tao WU ; Lyuhui HU ; Bingmei ZHU ; Zhihua YE ; Zhizhen TAO ; Min YANG ; Qinxi LIU ; Bihui YANG ; Hang LUO ; Fan QU ; Yi YANG
China Modern Doctor 2025;63(24):68-72,129
Objective To analyze the medication rules of traditional Chinese medicine in treating breast cancer based on real-world data mining.Methods Inpatients with breast cancer who received traditional Chinese medicine treatment at the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine from January 2017 to December 2021 were selected.Python 3.10 software was used to mine traditional Chinese medicine prescription data;SPSS 23.0 software was applied for descriptive analysis,and systematic cluster analysis was performed on high-frequency drugs.Results A total of 3026 consultation records of inpatients with breast cancer were collected.The main traditional Chinese medicine syndrome diagnosis of"predominantly liver depression and Qi stagnation"accounted for 60.94%of the total consultations.A total of 240 kinds of traditional Chinese medicine were used,with a cumulative frequency of 35 462 times.Among them,29 kinds of traditional Chinese medicine such as Danggui,Fuling,Baizhu,Chaihu had a cumulative usage frequency exceeding 300 times.Regarding the four natures of drugs,cold-natured(43.55%),warm-natured(30.05%),and neutral-natured(23.34%)drugs were predominant;In terms of five flavors,sweet(46.12%),bitter(30.91%),and pungent(20.02%)were the main ones.The most frequently used drugs were tonifying herbs(32.77%),followed by heat-clearing herbs(15.96%)and phlegm-resolving herbs(14.71%).Systematic cluster analysis yielded 7 groups of drug combinations.Conclusion In real-world clinical practice,traditional Chinese medicine for breast cancer mainly uses tonifying herbs,reflecting the traditional Chinese medicine principle of"strengthening healthy Qi and cultivating the root"in treating tumors.The four natures and five flavors of drugs follow syndrome differentiation and the combination of cold and heat.The clustered drug combinations have extensive therapeutic effects,covering various syndromes of breast cancer at different stages,which can provide a reference for clinical medication.
4.Mechanism of BIM-induced ibrutinib resistance in chronic lymphocytic leukemia
Jiale ZHANG ; Bihui PAN ; Jiazhu WU ; Yilin KONG ; Li WANG ; Wei XU
Chinese Journal of Hematology 2025;46(2):152-160
Objective:To investigate the relationship between the BCL2 family protein BIM and ibrutinib resistance in chronic lymphocytic leukemia (CLL) and to analyze its regulatory mechanisms on apoptosis and autophagy.Methods:RNA sequencing (RNA-seq) was used to examine changes in the expression of BCL2 family proteins in samples from patients with CLL, MEC1 cell lines, and ibrutinib-resistant cell lines (MR). Western blot was used to analyze changes in BIM protein expression during apoptosis in MR. shRNA knockdown was used to assess the effects of BIM on cell proliferation and apoptosis. RNA-seq and the autophagy inhibitor chloroquine treatment were used to study autophagy-related changes in MR.Results:BIM expression was significantly downregulated before and after drug resistance in CLL primary cells and MEC1 cell lines ( P<0.0001). Knockdown of BIM in CLL cells inhibited ibrutinib-induced apoptosis and promoted cell proliferation ( P<0.05 for both). In addition, protective autophagy was increased in MR and apoptosis was increased after administration of chloroquine and small interfering RNA. The increased expression of LC3-Ⅱ protein in BIM-knockdown cell lines ( P<0.01) suggested that reduction of BIM may mediate autophagy activation. Conclusion:Downregulation of BIM may be a key factor in promoting ibrutinib resistance in CLL by activating protective autophagy. These findings provided a potential target for improving CLL treatment.
5.Projecting the Dynamic Trends of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome:Modeling the Epidemic in Sichuan Province,China
Li YUAN ; Liu QINXI ; Luan RONGSHENG ; Yang YI ; Wu TAO ; Yang BIHUI
Biomedical and Environmental Sciences 2024;37(9):1003-1014
Objective Our study aimed to provide a comprehensive overview of the current status and dynamic trends of the human immunodeficiency virus (HIV) prevalence in Sichuan,the second most heavily affected province in China,and to explore future interventions. Methods The epidemiological,behavioral,and population census data from multiple sources were analyzed to extract inputs for an acquired immunodeficiency syndrome (AIDS) epidemic model (AEM). Baseline curves,derived from historical trends in HIV prevalence,were used,and the AEM was employed to examine future intervention scenarios. Results In 2015,the modeled data suggested an adult HIV prevalence of 0.191% in Sichuan,with an estimated 128,766 people living with HIV/AIDS and 16,983 individuals with newly diagnosed infections. Considering current high-risk behaviors,the model predicts an increase in the adult prevalence to 0.306% by 2025,projecting an estimated 212,168 people living with HIV/AIDS and 16,555 individuals with newly diagnosed infections. Conclusion Heterosexual transmission will likely emerge as the primary mode of AIDS transmission in Sichuan. Furthermore,we anticipate a stabilization in the incidence of AIDS with a concurrent increase in prevalence. Implementing comprehensive intervention measures aimed at high-risk groups could effectively alleviate the spread of AIDS in Sichuan.
6.The efficacy and safety of thioamide in maintenance therapy for peripheral T-cell lymphoma
Hua YIN ; Jinhua LIANG ; Jiazhu WU ; Yue LI ; Xinyu ZHANG ; Yilin KONG ; Bihui PAN ; Li WANG ; Jianyong LI ; Wei XU ; Haorui SHEN
Chinese Journal of Hematology 2024;45(12):1091-1097
Objective:This study aimed to assess the efficacy and safety of thioamide as a maintenance therapy for peripheral T-cell lymphoma (PTCL) .Methods:This study retrospectively analyzed the data from 58 patients with PTCL who were treated in the Department of Hematology at the First Affiliated Hospital of Nanjing Medical University from January 2015 to July 2022. Chidamide was orally administered as a maintenance therapy after first-line or salvage treatment. Progression-free survival (PFS), overall survival (OS), and safety were analyzed.Results:Among the 58 patients with PTCL, 43 were males and 15 were females, and the median age was 66 (range: 29-83) years. Thirty-nine patients received thioamide as first-line maintenance therapy, and 19 patients received thioamide as maintenance therapy after salvage treatment. The median maintenance therapy duration was 16 months (range: 1-72 months), with a median PFS time of 33 (2-74) months, and the median OS time had not been reached. Patients who received first-line maintenance therapy with thioamide demonstrated superior PFS and OS outcomes compared with patients who received thioamide maintenance therapy after salvage treatment (median PFS time: not reached vs 7 months, P<0.001; median OS time: not reached vs 67 months, P=0.009). The most prevalent adverse reaction was a hematologic adverse reaction (77.6%). Twelve (20.7%) patients underwent a dose reduction and three patients discontinued treatment. Conclusion:Patients receiving thioamide maintenance therapy demonstrated a promising PFS and OS with a manageable safety profile, especially as the first-line maintenance therapy.
7.Expression and prognostic value of amphiregulin and interleukin-10 in cervical cancer
Wu YUFENG ; Wang BIHUI ; Chen ZHIFANG
Chinese Journal of Clinical Oncology 2024;51(23):1206-1211
Objective:To evaluate the expression of amphiregulin(AREG)and interleukin-10(IL-10)in tissues and peripheral blood from pa-tients with cervical cancer(CC)and to explore their relationship with patient prognosis.Methods:Cervical cancer tissues of 40 cervical can-cer patients admitted to The First Affiliated Hospital of Xinjiang Medical University from Jan 2017 to Dec 2018 were collected as the cervical cancer group,and the cervical tissues of 30 patients with negative screening results of uterine fibroids were selected as the control group.Immunohistochemistry(IHC)was performed to compare AREG and IL-10 expression between the two groups.Serum samples from 100 patients with CC(cervical cancer group)and 60 normal healthy individuals(control group)admitted during the same period were ana-lyzed for AREG and IL-10 expression using enzyme-linked immunosorbent assay(ELISA).Pearson correlation analysis was used to evaluate the relationship between AREG and IL-10.The 100 patients with cervical cancer were assigned into survivor(80 patients)and deceased(20 patients)groups.A Kaplan-Meier plot was used to analyze the relationship between AREG and IL-10 expression and the survival rates among patients with CC.Binary Logistic regression and receiver operating characteristic curve(ROC)analyses were performed to evaluate prognostic factors.Results:IHC results indicated that AREG and IL-10 were highly expressed in CC tissues compared to normal tissues(P<0.05).ELISA results revealed significantly elevated serum levels of AREG and IL-10 in cancer patients(P<0.000 1).Pearson correlation ana-lysis showed that AREG correlated positively with IL-10(P<0.05,r=0.593 6).Binary Logistic regression analysis identified AREG,IL-10,and lymph node metastasis as independent risk factors impacting survival of patients with CC(all P<0.05).ROC curve analysis showed AREG and IL-10 had high predictive value for survival(AUC=0.897 and 0.874,respectively).Conclusions:Increased AREG and IL-10 expression in tissues and serum of patients with CC suggest that AREG and IL-10 are closely related with the occurrence and progression of the disease.These biomarkers hold significant clinical value for predicting the prognosis of patients with CC.
8.Expression and prognostic value of amphiregulin and interleukin-10 in cervical cancer
Wu YUFENG ; Wang BIHUI ; Chen ZHIFANG
Chinese Journal of Clinical Oncology 2024;51(23):1206-1211
Objective:To evaluate the expression of amphiregulin(AREG)and interleukin-10(IL-10)in tissues and peripheral blood from pa-tients with cervical cancer(CC)and to explore their relationship with patient prognosis.Methods:Cervical cancer tissues of 40 cervical can-cer patients admitted to The First Affiliated Hospital of Xinjiang Medical University from Jan 2017 to Dec 2018 were collected as the cervical cancer group,and the cervical tissues of 30 patients with negative screening results of uterine fibroids were selected as the control group.Immunohistochemistry(IHC)was performed to compare AREG and IL-10 expression between the two groups.Serum samples from 100 patients with CC(cervical cancer group)and 60 normal healthy individuals(control group)admitted during the same period were ana-lyzed for AREG and IL-10 expression using enzyme-linked immunosorbent assay(ELISA).Pearson correlation analysis was used to evaluate the relationship between AREG and IL-10.The 100 patients with cervical cancer were assigned into survivor(80 patients)and deceased(20 patients)groups.A Kaplan-Meier plot was used to analyze the relationship between AREG and IL-10 expression and the survival rates among patients with CC.Binary Logistic regression and receiver operating characteristic curve(ROC)analyses were performed to evaluate prognostic factors.Results:IHC results indicated that AREG and IL-10 were highly expressed in CC tissues compared to normal tissues(P<0.05).ELISA results revealed significantly elevated serum levels of AREG and IL-10 in cancer patients(P<0.000 1).Pearson correlation ana-lysis showed that AREG correlated positively with IL-10(P<0.05,r=0.593 6).Binary Logistic regression analysis identified AREG,IL-10,and lymph node metastasis as independent risk factors impacting survival of patients with CC(all P<0.05).ROC curve analysis showed AREG and IL-10 had high predictive value for survival(AUC=0.897 and 0.874,respectively).Conclusions:Increased AREG and IL-10 expression in tissues and serum of patients with CC suggest that AREG and IL-10 are closely related with the occurrence and progression of the disease.These biomarkers hold significant clinical value for predicting the prognosis of patients with CC.
9.The efficacy and safety of thioamide in maintenance therapy for peripheral T-cell lymphoma
Hua YIN ; Jinhua LIANG ; Jiazhu WU ; Yue LI ; Xinyu ZHANG ; Yilin KONG ; Bihui PAN ; Li WANG ; Jianyong LI ; Wei XU ; Haorui SHEN
Chinese Journal of Hematology 2024;45(12):1091-1097
Objective:This study aimed to assess the efficacy and safety of thioamide as a maintenance therapy for peripheral T-cell lymphoma (PTCL) .Methods:This study retrospectively analyzed the data from 58 patients with PTCL who were treated in the Department of Hematology at the First Affiliated Hospital of Nanjing Medical University from January 2015 to July 2022. Chidamide was orally administered as a maintenance therapy after first-line or salvage treatment. Progression-free survival (PFS), overall survival (OS), and safety were analyzed.Results:Among the 58 patients with PTCL, 43 were males and 15 were females, and the median age was 66 (range: 29-83) years. Thirty-nine patients received thioamide as first-line maintenance therapy, and 19 patients received thioamide as maintenance therapy after salvage treatment. The median maintenance therapy duration was 16 months (range: 1-72 months), with a median PFS time of 33 (2-74) months, and the median OS time had not been reached. Patients who received first-line maintenance therapy with thioamide demonstrated superior PFS and OS outcomes compared with patients who received thioamide maintenance therapy after salvage treatment (median PFS time: not reached vs 7 months, P<0.001; median OS time: not reached vs 67 months, P=0.009). The most prevalent adverse reaction was a hematologic adverse reaction (77.6%). Twelve (20.7%) patients underwent a dose reduction and three patients discontinued treatment. Conclusion:Patients receiving thioamide maintenance therapy demonstrated a promising PFS and OS with a manageable safety profile, especially as the first-line maintenance therapy.
10.Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients
Fuxi LI ; Junzhao YE ; Yanhong SUN ; Yansong LIN ; Tingfeng WU ; Congxiang SHAO ; Qianqian MA ; Xianhua LIAO ; Shiting FENG ; Bihui ZHONG
Diabetes & Metabolism Journal 2021;45(3):417-429
Background:
Excessive delivery of free fatty acids (FFAs) to the liver promotes steatosis and insulin resistance (IR), with IR defined as reduced glucose uptake, glycogen synthesis and anti-lipolysis stimulated by normal insulin levels. Whether the associations between FFAs and diabetes development differ between patients with and without nonalcoholic fatty liver disease (NAFLD) remains unclear.
Methods:
Consecutive subjects (2,220 NAFLD subjects and 1,790 non-NAFLD subjects according to ultrasound imaging) were enrolled from the First Affiliated Hospital of Sun Yat-sen University between 2009 and 2019. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated.
Results:
There was an approximate J-shaped relationship between FFA levels and HOMA-IR in the NAFLD group. Higher FFA concentration quartiles were associated with higher risks of IR (odds ratio [OR], 9.24; 95% confidence interval [CI], 6.43 to 13.36), prediabetes (OR, 10.48; 95% CI, 5.66 to 19.39), and type 2 diabetes mellitus (T2DM; OR, 19.43; 95% CI, 12.75 to 29.81) in the NAFLD group but not in the non-NAFLD group. The cut-off points for the FFA levels increased in a stepwise manner in discriminating IR, prediabetes and T2DM (573, 697, and 715 μmol/L) in the NAFLD group but not in non-NAFLD individuals.
Conclusion
A distinct dose-dependent relationship of FFA levels was found with IR, prediabetes and T2DM in NAFLD patients. Screening serum FFA levels in NAFLD patients would be valuable in preventing diabetes development.

Result Analysis
Print
Save
E-mail